Home / Healthcare / US Market Changes in the Treatment of Advanced Prostate Cancer

US Market Changes in the Treatment of Advanced Prostate Cancer

Published: Sep 2012 | No Of Pages: 30 | Published By: Assessment Group
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 to compare oncology practice patterns and determine trends across time in the management of advanced prostate cancer.
This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing U.S. oncologists on the treatment of patients with advanced prostate cancer.

Chapter 1: Introduction 5

Chapter 2: Respondent Demographics 6

Chapter 3: Treatment of a Patient with Increased PSA and Adenocarcinoma 10

Chapter 4: Elderly Patient Treated for Gleasons 7 Adenocarcinoma, Increased PSA 18 Months Later 15

Chapter 5: Patient with Gleasons 3+4 Adenocarcinoma and Multiple Metastases to Pelvis
and Spine Develops Castration-resistant Disease 20

Chapter 6: Elderly Patient with Gleasons 5+5 and Multiple Metastases 24

Appendix A: Survey Instrument 26
Choose License Type
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +